Morgan Stanley Reiterates Overweight on Omada Health, Maintains $30 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 74.4%

Neg 0% Neu 74.4% Pos 0%

Morgan Stanley analyst Craig Hettenbach reiterates Omada Health (NASDAQ:OMDA) with a Overweight and maintains $30 price target.